Compass Therapeutics, Inc. (CMPX)
2.52
+0.12
(+5.00%)
USD |
NASDAQ |
Aug 25, 16:00
2.50
-0.02
(-0.79%)
After-Hours: 19:01
Compass Therapeutics Shareholders Equity (Quarterly) : 166.05M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 166.05M |
| March 31, 2026 | 186.47M |
| December 31, 2025 | 196.79M |
| September 30, 2025 | 209.61M |
| June 30, 2025 | 93.21M |
| March 31, 2025 | 110.28M |
| December 31, 2024 | 125.23M |
| September 30, 2024 | 138.40M |
| June 30, 2024 | 146.10M |
| March 31, 2024 | 157.06M |
| December 31, 2023 | 148.54M |
| September 30, 2023 | 160.04M |
| June 30, 2023 | 168.29M |
| March 31, 2023 | 175.26M |
| Date | Value |
|---|---|
| December 31, 2022 | 181.64M |
| September 30, 2022 | 116.12M |
| June 30, 2022 | 126.93M |
| March 31, 2022 | 134.49M |
| December 31, 2021 | 140.08M |
| September 30, 2021 | 23.89M |
| June 30, 2021 | 28.88M |
| March 31, 2021 | 33.47M |
| December 31, 2020 | 39.94M |
| September 30, 2020 | 47.29M |
| June 30, 2020 | 53.25M |
| March 31, 2020 | -124.76M |
| December 31, 2019 | -118.60M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Upstream Bio, Inc. | 270.96M |
| ACADIA Pharmaceuticals, Inc. | 1.307B |
| Alnylam Pharmaceuticals, Inc. | 1.354B |
| Anika Therapeutics, Inc. | 137.28M |
| Savara, Inc. | 143.66M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 190.17M |
| Total Liabilities (Quarterly) | 24.12M |
| Debt to Equity Ratio | 0.058 |
| Current Ratio | 11.22 |
| Net Debt Paydown Yield | -0.16% |